GH1 and Alzheimer disease: Other distinctions between the Aβ-positive hGH recipients and Alzheimer’s disease patients include the notable absence of neurofibrillary tangles, a paucity of phospho-tau-positive neurites around neuritic plaques, the young age at death of the hGH recipients and the absence of a clinical history of slowly progressive cognitive impairment.